報價延遲最少15分鐘:2025/05/13 21:46 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.81 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.35/-3.89
|
|
企業價值
1.09B
|
| 資產負債 |
|
每股賬面淨值
5.09
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
302.00K
|
|
每股收益
0.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/13 21:46 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly knownas VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |